Krebs Biochemicals & Industries Ltd. (IN:KREBSBIO)
:KREBSBIO
KREBSBIO Stock Chart & Stats
₹71.00
-₹2.80(-2.89%)
At close: 4:00 PM EST
₹71.00
-₹2.80(-2.89%)
Day’s Range― - ―
52-Week Range₹38.52 - ₹113.90
Previous CloseN/A
Volume3.29K
Average Volume (3M)726.00
Market Cap
₹1.27B
Enterprise Value₹3.53B
Total Cash (Recent Filing)₹1.27M
Total Debt (Recent Filing)₹2.19B
Price to Earnings (P/E)―
Beta1.76
Next Earnings
May 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.45
Shares Outstanding21,560,587
10 Day Avg. Volume346
30 Day Avg. Volume726
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)-1.00
Price to Sales (P/S)3.37
P/FCF Ratio-12.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
B2B Manufacturing ModelKrebs' core revenue comes from selling manufactured biochemical and chemical products to industrial buyers. B2B supply relationships are often contract-driven and recurrent, providing customer stickiness and revenue visibility that support operational stability over a multi-month horizon.
Industry PositioningOperating in the specialty & generic pharmaceutical supply chain exposes Krebs to structurally durable demand for biochemical inputs. Regulatory complexity and long product cycles create entry barriers, favoring incumbent suppliers and supporting steady mid-term demand for established producers.
Public Listing / Capital AccessAs a publicly listed company on the NSE, Krebs retains formal access to capital markets and enhanced disclosure discipline. This status preserves options to pursue equity raises, debt refinancings or strategic partnerships that can materially improve balance sheet flexibility over several months if executed.
Bears Say
Persistent Unprofitable OperationsKrebs has sustained negative net income and EBIT margins across reporting periods, signaling operational losses that erode reinvestment capacity. Continued unprofitability weakens competitive positioning, reduces ability to fund improvements, and increases reliance on external financing over the medium term.
Negative Equity And High LeverageThe balance sheet shows negative shareholders' equity and heavy leverage, creating elevated insolvency and refinancing risk. High leverage limits negotiating power with lenders and suppliers and constrains strategic choices, making structural recapitalization or deleveraging necessary to restore financial health.
Poor Cash GenerationChronic negative operating and free cash flows indicate the company is not converting operations into cash, restricting its ability to meet obligations or invest in maintenance and growth. Persistent cash burn increases dependency on external funding, risking dilution or tighter credit terms.
Krebs Biochemicals & Industries Ltd. News
KREBSBIO FAQ
What was Krebs Biochemicals & Industries Ltd.’s price range in the past 12 months?
Krebs Biochemicals & Industries Ltd. lowest stock price was ₹38.52 and its highest was ₹113.90 in the past 12 months.
What is Krebs Biochemicals & Industries Ltd.’s market cap?
Krebs Biochemicals & Industries Ltd.’s market cap is ₹1.27B.
When is Krebs Biochemicals & Industries Ltd.’s upcoming earnings report date?
Krebs Biochemicals & Industries Ltd.’s upcoming earnings report date is May 26, 2026 which is in 43 days.
How were Krebs Biochemicals & Industries Ltd.’s earnings last quarter?
Krebs Biochemicals & Industries Ltd. released its earnings results on Feb 09, 2026. The company reported -₹1.45 earnings per share for the quarter, missing the consensus estimate of N/A by -₹1.45.
Is Krebs Biochemicals & Industries Ltd. overvalued?
According to Wall Street analysts Krebs Biochemicals & Industries Ltd.’s price is currently Overvalued.
Does Krebs Biochemicals & Industries Ltd. pay dividends?
Krebs Biochemicals & Industries Ltd. does not currently pay dividends.
What is Krebs Biochemicals & Industries Ltd.’s EPS estimate?
Krebs Biochemicals & Industries Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Krebs Biochemicals & Industries Ltd. have?
Krebs Biochemicals & Industries Ltd. has 21,560,587 shares outstanding.
What happened to Krebs Biochemicals & Industries Ltd.’s price movement after its last earnings report?
Krebs Biochemicals & Industries Ltd. reported an EPS of -₹1.45 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.018%.
Which hedge fund is a major shareholder of Krebs Biochemicals & Industries Ltd.?
Currently, no hedge funds are holding shares in IN:KREBSBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Krebs Biochemicals & Industries Ltd.
Krebs Biochemicals & Industries Limited manufactures and sells active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry fields. Its products, such as androstenedione, lovastatin, and simvastatin for anti-cholesterol and steroid intermediate applications. The company is also developing various products, including amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine for anti-hypertension, anti-histamine, anti-obesity, anti-inflammatory, and cold and cough applications. In addition, it offers contract manufacturing services for large pharmaceutical and multinational companies. Krebs Biochemicals & Industries Limited was incorporated in 1991 and is headquartered in Hyderabad, India.
Technical Analysis
Aarey Drugs & Pharmaceuticals Ltd.
―
Alpa Laboratories Limited
―
Bafna Pharmaceuticals Limited
―
Bal Pharma Limited
―
Vaishali Pharma Ltd.
―